-+ 0.00%
-+ 0.00%
-+ 0.00%

PureTech's Vedanta Biosciences Publishes Phase 2 VE303 Results In Nature Medicine, Highlighting Multi-Mechanism Approach To Prevent rCDI

Benzinga·01/27/2025 07:14:26
Listen to the news
  • VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms
  • Analyses identified predictors of VE303 colonization and protection from CDI recurrence
  • Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026